FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W58289321> ?p ?o ?g. }

• W58289321 endingPage "522" @default.
• W58289321 startingPage "519" @default.
• W58289321 abstract "No AccessJournal of Urology1 Mar 1993Prostate Specific Antigen after External Beam Radiotherapy for Prostatic Cancer: Followup Irving D. Kaplan, Richard S. Cox, and Malcolm A. Bagshaw Irving D. KaplanIrving D. Kaplan More articles by this author , Richard S. CoxRichard S. Cox More articles by this author , and Malcolm A. BagshawMalcolm A. Bagshaw More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)36133-5AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Between 1986 and 1989, 117 patients with pretreatment and serial posttreatment prostate specific antigen values received external beam radiotherapy at our hospital. Followup ranged from 0.6 to 5.9 years (mean 2.7). No patient had hormonal manipulation before distant recurrence. Biochemical relapse, defined as an increasing prostate specific antigen level after treatment, was observed in 44 patients. To date 30 of these 44 patients (68%) have had clinical relapse. The prognostic factors of advanced local stage, high Gleason score and high elevations of pretreatment prostate specific antigen values predicted for biochemical relapse and subsequent clinical failure. The interval between biochemical and clinical relapse was 156 ± 46 days. Biochemical relapse is an important end point that can be used to determine the effect of treatment in prostatic cancer research. © 1993 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byHORWITZ E, UZZO R, HANLON A, GREENBERG R, HANKS G and POLLACK A (2018) Modifying the American Society for Therapeutic Radiology and Oncology Definition of Biochemical Failure to Minimize the Influence of Backdating in Patients With Prostate Cancer Treated With 3-dimensional Conformal Radiation Therapy AloneJournal of Urology, VOL. 169, NO. 6, (2153-2159), Online publication date: 1-Jun-2003.Rosser C, Chichakli R, Levy L, Kuban D, Smith L and Pisters L (2018) Biochemical Disease-Free Survival in Men Younger Than 60 Years With Prostate Cancer Treated With External Beam RadiationJournal of Urology, VOL. 168, NO. 2, (536-541), Online publication date: 1-Aug-2002.VAIDYA A and SOLOWAY M (2018) SALVAGE RADICAL PROSTATECTOMY FOR RADIORECURRENT PROSTATE CANCER: : MORBIDITY REVISITEDJournal of Urology, VOL. 164, NO. 6, (1998-2001), Online publication date: 1-Dec-2000.AMLING C, LERNER S, MARTIN S, SLEZAK J, BLUTE M and ZINCKE H (2018) DEOXYRIBONUCLEIC ACID PLOIDY AND SERUM PROSTATE SPECIFIC ANTIGEN PREDICT OUTCOME FOLLOWING SALVAGE PROSTATECTOMY FOR RADIATION REFRACTORY PROSTATE CANCERJournal of Urology, VOL. 161, NO. 3, (857-863), Online publication date: 1-Mar-1999.GARZOTTO M and WAJSMAN Z (2018) ANDROGEN DEPRIVATION WITH SALVAGE SURGERY FOR RADIORECURRENT PROSTATE CANCER: RESULTS AT 5-YEAR FOLLOWUPJournal of Urology, VOL. 159, NO. 3, (950-955), Online publication date: 1-Mar-1998.Vicini F, Horwitz E, Gonzalez J and Martinez A (2018) Treatment Options for Localized Prostate Cancer Based on Pretreatment Serum Prostate Specific Antigen LevelsJournal of Urology, VOL. 158, NO. 2, (319-325), Online publication date: 1-Aug-1997.Lee W, Hanlon A and Hanks G (2018) Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate Cancer: The relationship between nadir level and disease-free survivalJournal of Urology, VOL. 156, NO. 2, (450-453), Online publication date: 1-Aug-1996.Roach M, Meehan S, Kroll S, Weil M, Ryu J, Small E, Margolis L, Presti J, Carroll P and Phillips T (2018) Radiotherapy for High Grade Clinically Localized Adenocarcinoma of the ProstateJournal of Urology, VOL. 156, NO. 5, (1719-1723), Online publication date: 1-Nov-1996.Lerner S, Blute M and Zincke H (2018) Critical Evaluation of Salvage Surgery for Radio-Recurrent/Resistant Prostate CancerJournal of Urology, VOL. 154, NO. 3, (1103-1109), Online publication date: 1-Sep-1995.Rogers E, Ohori M, Kassabian V, Wheeler T and Scardino P (2018) Salvage Radical Prostatectomy: Outcome Measured by Serum Prostate Specific Antigen LevelsJournal of Urology, VOL. 153, NO. 1, (104-110), Online publication date: 1-Jan-1995.Rosenzweig K, Morgan W, Lytton B and Peschel R (2018) Prostate Specific Antigen Following Radiotherapy for Local Prostate CancerJournal of Urology, VOL. 153, NO. 5, (1561-1564), Online publication date: 1-May-1995.McKenzie M (2018) Re: The Value of Serial Prostate Specific Antigen Determinations 5 Years After RadiotherapyJournal of Urology, VOL. 153, NO. 6, (1953-1954), Online publication date: 1-Jun-1995.Bagshaw M, Cox R and Hancock S (2018) Control of Prostate Cancer with Radiotherapy: Long-Term ResultsJournal of Urology, VOL. 152, NO. 5 Part 2, (1781-1785), Online publication date: 1-Nov-1994.Zagars G (2018) Prostate Specific Antigen as an Outcome Variable for T1 and T2 Prostate Cancer Treated by Radiation TherapyJournal of Urology, VOL. 152, NO. 5 Part 2, (1786-1791), Online publication date: 1-Nov-1994.Leibel S, Zelefsky M, Kutcher G, Burman C, Kelson S and Fuks Z (2018) Three-Dimensional Conformal Radiation Therapy in Localized Carcinoma of The Prostate: Interim Report of A Phase 1 Dose-Escalation StudyJournal of Urology, VOL. 152, NO. 5 Part 2, (1792-1798), Online publication date: 1-Nov-1994.Zietman A, Shipley W and Coen J (2018) Radical Prostatectomy and Radical Radiation Therapy for Clinical Stages T1 to 2 Adenocarcinoma of the Prostate: New Insights into Outcome from Repeat Biopsy and Prostate Specific Antigen FollowupJournal of Urology, VOL. 152, NO. 5 Part 2, (1806-1812), Online publication date: 1-Nov-1994.Trapasso J, Dekernion J, Smith R and Dorey F (2018) The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical ProstatectomyJournal of Urology, VOL. 152, NO. 5 Part 2, (1821-1825), Online publication date: 1-Nov-1994.Partin A and Oesterling J (2018) The Clinical Usefulness of Prostate Specific Antigen: Update 1994Journal of Urology, VOL. 152, NO. 5 Part 1, (1358-1368), Online publication date: 1-Nov-1994.Parsons J and Zlotecki R (2018) Re: The Value of Serial Prostate Specific Antigen Determinations 5 Years after Radiotherapy: Steeply Increasing Values Characterize 80% of Patients, T. A. Stamey, M. K. Ferrari and H.-P. Schmid J. Urol., 150: 1856–1859, 1993Journal of Urology, VOL. 152, NO. 5 Part 1, (1564-1564), Online publication date: 1-Nov-1994.Kaplan I and Coleman C (2018) Re: The Value of Serial Prostate Specific Antigen Determinations 5 Years after Radiotherapy: Steeply Increasing Values Characterize 80% of Patients, by T. A. Stamey, M. K. Ferrari and H.-P. Schmid, J. Urol., 150: 1856–1859, 1993 and Re: Editorial: Prostate Cancer, by C. B. Brendler, J. Urol., 150: 1865–1866, 1993Journal of Urology, VOL. 152, NO. 2 Part 1, (493-494), Online publication date: 1-Aug-1994.Zietman A, Coen J, Shipley W, Willett C and Efird J (2018) Radical Radiation Therapy in the Management of Prostatic Adenocarcinoma: The Initial Prostate Specific Antigen Value as a Predictor of Treatment OutcomeJournal of Urology, VOL. 151, NO. 3, (640-645), Online publication date: 1-Mar-1994.Willett C, Zietman A, Shipley W and Coen J (2018) The Effect of Pelvic Radiation Therapy on Serum Levels of Prostate Specific AntigenJournal of Urology, VOL. 151, NO. 6, (1579-1581), Online publication date: 1-Jun-1994.Stamey T, Ferrari M and Schmid H (2018) The Value of Serial Prostate Specific Antigen Determinations 5 Years after Radiotherapy: Steeply Increasing Values Characterize 80% of PatientsJournal of Urology, VOL. 150, NO. 6, (1856-1859), Online publication date: 1-Dec-1993. Volume 149Issue 3March 1993Page: 519-522 Advertisement Copyright & Permissions© 1993 by The American Urological Association Education and Research, Inc.Keywordsradiotherapyantigens, neoplasmprostatic neoplasmsMetricsAuthor Information Irving D. Kaplan More articles by this author Richard S. Cox More articles by this author Malcolm A. Bagshaw More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W58289321 created "2016-06-24" @default.
• W58289321 creator A5006660870 @default.
• W58289321 creator A5032089356 @default.
• W58289321 creator A5062315544 @default.
• W58289321 date "1993-03-01" @default.
• W58289321 modified "2023-09-23" @default.
• W58289321 title "Prostate Specific Antigen after External Beam Radiotherapy for Prostatic Cancer: Followup" @default.
• W58289321 cites W11097077 @default.
• W58289321 cites W1525744048 @default.
• W58289321 cites W2143594378 @default.
• W58289321 cites W2407883661 @default.
• W58289321 cites W2418785680 @default.
• W58289321 cites W2421508658 @default.
• W58289321 cites W38417416 @default.
• W58289321 cites W4293241248 @default.
• W58289321 cites W53877061 @default.
• W58289321 cites W96058809 @default.
• W58289321 doi "https://doi.org/10.1016/s0022-5347(17)36133-5" @default.
• W58289321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7679756" @default.
• W58289321 hasPublicationYear "1993" @default.
• W58289321 type Work @default.
• W58289321 sameAs 58289321 @default.
• W58289321 citedByCount "181" @default.
• W58289321 countsByYear W582893212013 @default.
• W58289321 countsByYear W582893212015 @default.
• W58289321 countsByYear W582893212016 @default.
• W58289321 crossrefType "journal-article" @default.
• W58289321 hasAuthorship W58289321A5006660870 @default.
• W58289321 hasAuthorship W58289321A5032089356 @default.
• W58289321 hasAuthorship W58289321A5062315544 @default.
• W58289321 hasConcept C121608353 @default.
• W58289321 hasConcept C126322002 @default.
• W58289321 hasConcept C126894567 @default.
• W58289321 hasConcept C143998085 @default.
• W58289321 hasConcept C2775908122 @default.
• W58289321 hasConcept C2776235491 @default.
• W58289321 hasConcept C2780192828 @default.
• W58289321 hasConcept C2781406297 @default.
• W58289321 hasConcept C509974204 @default.
• W58289321 hasConcept C71924100 @default.
• W58289321 hasConceptScore W58289321C121608353 @default.
• W58289321 hasConceptScore W58289321C126322002 @default.
• W58289321 hasConceptScore W58289321C126894567 @default.
• W58289321 hasConceptScore W58289321C143998085 @default.
• W58289321 hasConceptScore W58289321C2775908122 @default.
• W58289321 hasConceptScore W58289321C2776235491 @default.
• W58289321 hasConceptScore W58289321C2780192828 @default.
• W58289321 hasConceptScore W58289321C2781406297 @default.
• W58289321 hasConceptScore W58289321C509974204 @default.
• W58289321 hasConceptScore W58289321C71924100 @default.
• W58289321 hasIssue "3" @default.
• W58289321 hasLocation W582893211 @default.
• W58289321 hasLocation W582893212 @default.
• W58289321 hasOpenAccess W58289321 @default.
• W58289321 hasPrimaryLocation W582893211 @default.
• W58289321 hasRelatedWork W1980188241 @default.
• W58289321 hasRelatedWork W1992657261 @default.
• W58289321 hasRelatedWork W2038565121 @default.
• W58289321 hasRelatedWork W2148869351 @default.
• W58289321 hasRelatedWork W2373651588 @default.
• W58289321 hasRelatedWork W2897445903 @default.
• W58289321 hasRelatedWork W2944341298 @default.
• W58289321 hasRelatedWork W3129209394 @default.
• W58289321 hasRelatedWork W3163649103 @default.
• W58289321 hasRelatedWork W4281788288 @default.
• W58289321 hasVolume "149" @default.
• W58289321 isParatext "false" @default.
• W58289321 isRetracted "false" @default.
• W58289321 magId "58289321" @default.
• W58289321 workType "article" @default.